Holder snapshot 7 signals
Share change
+8,427,874
Put/Call ratio
16%
SEC-reported price per share
$34.57
Indexed holders
302
Value change
+$325,204,372
Number of buys
187
Open additional details 1 more signal available
Number of sells
107
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
195,164,384

Security key

10806X102

Report period

Q1 2025

Indexed institutions

302

Top holders

10

Ownership snapshot

Top reported holders of BBIO - BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (the "Shares") (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Kohlberg Kravis Roberts &...
Disclosed value leader
Kohlberg Kravis Roberts &...
Comparable rows
0/15
Latest evidence
31 Dec 2024
13F Highest disclosed value: $693,161,044 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Kohlberg Kravis Roberts & Co. L.P. has the largest disclosed position value at $693.16M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Kohlberg Kravis Roberts & Co. L.P.'s linked filing trail.
Disclosed position value Top 5
Kohlberg Kravis Roberts & Co. L.P. $693.16M
VIKING GLOBAL INVESTORS LP $689.32M
VANGUARD GROUP INC $413.74M
BlackRock, Inc. $376.19M
STATE STREET CORP $169.65M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Kohlberg Kravis Roberts & Co. L.P.
13F
Company
13F
—
denominator unverified
$693,161,044
25,260,971 shares
— 31 Dec 2024
VIKING GLOBAL INVESTORS LP
13F
Company
13F
—
denominator unverified
$689,319,993
25,120,991 shares
— 31 Dec 2024
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$413,737,987
15,077,915 shares
— 31 Dec 2024
BlackRock, Inc.
13F
Company
13F
—
denominator unverified
$376,192,685
13,709,646 shares
— 31 Dec 2024
STATE STREET CORP
13F
Company
13F
—
denominator unverified
$169,651,285
6,182,627 shares
— 31 Dec 2024
Aisling Capital Management LP
13F
Company
13F
—
denominator unverified
$166,509,350
6,068,125 shares
— 31 Dec 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
302
Shares
185,173,982
Indexed holders
302
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2025 vs Q4 2024 Across Filers

Q4 2024 indexed holders
260
Q1 2025 indexed holders
302
Indexed holder difference
42
Investor Q4 2024 Shares Q1 2025 Shares Share Diff Share Chg % Q4 2024 value Q1 2025 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .